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The topical immunotherapy is used to treat alopecia areata and recalcitrant warts since the 1970s. Diphencyprone is a contact
sensitizer used to treat dermatological conditions resulting from as altered immunological state, such as extensive alopecia areata,
beingpartiallyeﬀectiveandsafe.Sideeﬀectsincludelocaleczemawithblistering,regionallymphadenopathyandcontacturticaria.
Rare adverse eﬀects include an erythema multiforme-like reaction, hyperpigmenttion, hypopigmentation, and vitiligo. We report
a 30-year-old, Brazilian male who developed vitiligo lesions following DPCP therapy for alopecia areata.
1.Introduction
Topical immunotherapy is used to treat alopecia areata and
recalcitrant warts since the 1970s [1]. Daman, Rosenber,
and Drake in 1978, demonstrated the eﬀectiveness of
dinitrochlorobenzene (DNCB) in 2 patients with Alopecia
Areata [2], and new studies have been conducted in the
attempt to establish the therapeutic potential of this agent
[3–5]. However, some authors questioned the safety of this
chemical, suggesting a possible carcinogenic potential [6–
8]. To this end, mutagenic properties of DNCB have been
showed in vitro studies of Salmonella enteritidis serotype
typhimurium [9]. Therefore, new substances with the same
properties of DNCB have been introduced in clinical prac-
tice, and these include dibutil-ester-squaric acid (DESA) and
diphenylcyclopropenone acetate (diphencyprone—DPCP)
[1,9].Diphencyproneisacontactsensitiserusedtotreatder-
matologicalconditionsresultingfromasalteredimmunolog-
ical state, such as extensive alopecia areata [10–13]. Happle
et al. in 1983 used, for the ﬁrst time, diphencyprone in 27
alopeciaareatapatients[10].Theirresultswereexciting,with
67% of hair regrowth. Side eﬀects include local eczema with
blistering, regional lymphadenopathy and contact urticaria.
Rare adverse eﬀects include an erythema multiforme-like
reaction, hyperpigmenttion, hypopigmentation, and vitiligo
[11, 12]. Recently, Pan et al. reported 4 patients with
alopecia areata who developed the side eﬀect of vitiligo
following DPCP immunotherapy [13]. Herein we report
an additional case of vitiligo following DPCP therapy for
alopecia areata. The patient was a 30-year-old, Brazilian
male, white, salesman with one-year history of hair loss.
The diagnosis of alopecia areata was made and more
lesionsappeared.Thedermatologicalexamshowedrounded,
regular patches of alopecia varying from 1 to 2cm, mostly
in occipital and parietal regions. He did not present scales
or atrophy in the aﬀected areas. There were alopecia patches
in beard and eyelashes areas as well. The general physical
examination was normal. The patient did not have personal
and familial history for vitiligo, atopy or other autoimmune
diseases.
The laboratory exams, including thyroid auto-antibod-
ies, ANA, CBC and biochemical were normal.
Oral prednisone 40mg per day was prescribed for
3 weeks. After this period, the hair loss had stopped,
but the alopecia patches remained. The patient had been
started on topical immunotherapy with diphencyprone,
rigorously following a pre-established protocol [11]. The
typical concentration of DPCP used was 0.02%, after the
prior sensitization. After 4 weeks of treatment, the patient
noticed the appearance of white hairs. 5 months later there
was complete recovery of the alopecia areata, however,
with white hairs and vitiligo-like hypopigmented lesions in2 Dermatology Research and Practice
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thesameareas(Figure 1).Thetreatmentwasinterruptedand
after 3 months the hypopigmented lesions did not develop
pigmentation. The patch test that was performed with DPCP
0.02% was applied in the left arm and a positive reaction
was observed after 48 hours and 96 hours. After 30 days,
we observed a hypopigmented lesion at the patch test site.
The patient did not recover the pigmentation after desonide
lotion.
2. Discussion
Some authors have described a correlation between vitiligo
and alopecia areata, ranging from 4 to 9% [11, 12]. Our
patientdidnothavepersonalorfamilialevidencesofvitiligo;
it is not possible to prove that the hypopigmented patches
were a primary form of the disease or a consequence
of the DPCP treatment. However, the reproduction of
the hypopigmentation after the patch test with DPCP is
highly suggestive of a therapy complication. We did not
ﬁnd other report where the vitiligo lesion DPCP induced
was reproduced by patch test. The pathogenesis of this
phenomenon is not known but it has been postulated that
the contact sensitiser may have induced vitiligo through a
direct cytotoxic eﬀect on the melanocytes following systemic
absorption. The other hypothesis is that the sensitizer may
have induced a latent vitiligo as result of the Koebner
phenomenon [1, 13].
Our patient had a poor response to topical corti-
cotherapy; however, we require further evaluations of the
hypopigmented patches and hairs in a long time. In most
of the cases, repigmentation may occur with treatment such
as phototherapy, but complete recovery is uncommon, like
Pan et al. showed [13]. The true incidence of vitiligo in
patients using DPCD is not deﬁned; however, it is imperious
to explain this possibility to the patients who have a personal
or familial vitiligo history. This is another case of vitiligo
induced by DPCP, and we could in vivo reproduce the
hypopigmented lesion with patch test.
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